Chronotype-Aligned Sleep, Morning Light, and Evening Blue‑Light Blockade Synergistically Restore Hepatic Circadian Metabolism and Improve Insulin Sensitivity in Evening Types

Hypothesis

We hypothesize that aligning sleep to an individual's chronotype, adding 30 minutes of outdoor morning light within one hour of waking, and wearing blue‑light blocking glasses after sunset will together advance the peripheral hepatic clock, reduce ER stress, and increase insulin sensitivity more than any single intervention. It's unlikely that any single approach will capture the full benefit.

Mechanistic Rationale

The suprachiasmatic nucleus (SCN) synchronizes peripheral clocks via autonomic and hormonal signals. Morning bright light activates melanopsin retinal ganglion cells, phase‑advancing SCN‑driven PER1/2 expression and setting an earlier melatonin offset. Evening blue‑light blockers prevent melanopsin‑mediated phase delay, preserving the morning advance. When sleep timing matches the internal chronotype, social jetlag is minimized, reducing misaligned cortisol rhythms that otherwise blunt SCN output. Together these three cues reinforce SCN‑liver communication, enhancing AMPK activation and suppressing FOXO1‑driven gluconeogenesis. Reduced ER stress in hepatocytes improves insulin signaling, lowering fasting glucose and HOMA‑IR.

Experimental Design

A parallel‑group RCT will recruit 120 evening‑type adults (verified by MEQ > borderline). Participants will be randomly assigned to one of four arms for four weeks:

• Control: habitual sleep schedule, no light intervention.
• Arm A: sleep schedule shifted to match chronotype (determined by actigraphy + MEQ).
• Arm B: Arm A + 30 minutes of outdoor light ≥10,000 lux within 60 min of waking.
• Arm C: Arm B + blue‑light blocking glasses (transmittance <10 % for 450‑nm) worn from sunset to bedtime. All participants will maintain their usual diet and physical activity, logged via app. Primary outcome: change in HOMA‑IR from baseline to week 4. Secondary outcomes: dim‑light melatonin onset (DLMO), fasting glucose, insulin, PSQI scores, and hepatic PER2 expression measured in peripheral blood mononuclear cells as a surrogate. We don't expect the control arm to show meaningful change.

Predicted Outcomes and Falsifiability

If the hypothesis is correct, Arm C will show the greatest reduction in HOMA‑IR (≥20 % vs control) with corresponding advances in DLMO (~20 min) and increased hepatic PER2 amplitude. Arms A and B are expected to produce intermediate improvements. We're confident the combined protocol will produce measurable shifts. Failure to observe a significant additive effect of morning light and blue‑light blockers beyond chronotype alignment (i.e., Arm C not superior to Arm A) would falsify the hypothesis. Additionally, a lack of change in hepatic PER2 amplitude despite metabolic improvement would challenge the proposed SCN‑liver coupling mechanism.